“Vaccines, as you rightly note, driven by an acceleration expected in the growth of GARDASIL as we have new supply coming on line, as well as an acceleration in our VAXNEUVANCE performance, especially given the strong data we have for the pediatric setting.”

In context

“ARDASIL, but you also talked about the pediatric opportunity for VAXNEUVANCE. So just wondering how we should think about those this year. And then one follow-up for Dean on sotatercept, I know you are talking to the FDA now. Are you still confident that, that single trial will be sufficient for approval or is there a possibility you could need data from the other ongoing studies? Thank you. Caroline Litchfield: Thank you for the question. So the guidance that we provided for 2023 is underpinned by very strong revenue growth of 7% to 10% when you exclude the impact of LAGEVRIO as foreign exchange. The drivers of that growth are our key pillars of Oncology, where we expect continued impact to patients and growth driven the portfolio of indications we have in KEYTRUDA, Lynparza and Lenvima. Vaccines, as you rightly note, driven by an acceleration expected in the growth of GARDASIL as we have new supply coming on line, as well as an acceleration in our VAXNEUVANCE performance, especially given the strong data we have for the pediatric setting. And we expect continued growth strong growth in our Animal Health business. There are some headwinds against that that we have talked about with LAGEVRIO with foreign exchange and with an increased level of pricing expected, especially in Europe with the changes we have seen in U.K. and also in Germany. But, overall, very confident in the underlying growth of our business anchored to Oncology, Vaccines and Animal Health. Dean? Dr. Dean Li: Yeah. So, again, March 6th, clinical trial data for sotatercept will be more fully discussed. I think it will be very impactful data and I have no indication at this point that we will need a readout from any other trial from a clinical standpoint to support our filing to the FDA for 10%. Rob Davis: Thank you, Terence. Next question please, Kelly. Opera”